DD-723 Phase II clinical trial - Dose-response study in patients with breast tumor
Latest Information Update: 25 May 2016
Price :
$35 *
At a glance
- Drugs Perflubutane (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 25 May 2016 New trial record